Pathology of Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) represents a unique subtype characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. This track will delve into the intricate pathology of TNBC, exploring its clinical implications and therapeutic strategies. Attendees will gain insights into the aggressive nature of TNBC, its distinct molecular features, and the challenges associated with diagnosis and treatment. Discussion will focus on emerging biomarkers, novel targeted therapies, and immunotherapy approaches. By understanding the underlying pathology of TNBC, participants will be equipped to optimize patient management, improve prognostic evaluation, and contribute to the development of personalized therapeutic interventions.

 

 

    Related Conference of Pathology of Triple-Negative Breast Cancer

    July 14-15, 2025

    5th World Congress on Breast Cancer

    Berlin, Germany
    July 28-29, 2025

    45th Euro Congress on Cancer Science & Therapy

    Paris, France
    August 18-19, 2025

    6th Cancer Diagnostics & Treatment Conference

    Rome, Italy
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain
    October 22-23, 2025

    35th Experts Meet On Cancer Research & Therapy

    Paris, France
    October 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    Zurich, Switzerland
    November 24-25, 2025

    43rd World Cancer Conference

    Barcelona, Spain
    March 23-24, 2026

    16th World Congress on Breast Cancer Research & Therapies

    Aix-en-Provence, France

    Pathology of Triple-Negative Breast Cancer Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in